A phase i study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer: WJTOG 3305

Takuhito Tada, Yasutaka Chiba, Kayoko Tsujino, Haruyuki Fukuda, Yasumasa Nishimura, Masaki Kokubo, Shunichi Negoro, Shinzoh Kudoh, Masahiro Fukuoka, Kazuhiko Nakagawa, Yoichi Nakanishi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: A Phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small-cell lung cancer was conducted. Methods and Materials: Patients with unresectable Stage III non-small-cell lung cancer were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m 2) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m 2). Total doses were 54 Gy in 36 fractions, 60 Gy in 40 fractions, 66 Gy in 44 fractions, and 72 Gy in 48 fractions at Levels 1 to 4. The dose-limiting toxicity, defined as Grade ≥4 esophagitis and neutropenic fever and Grade ≥3 other nonhematologic toxicities, was monitored for 90 days. Results: Of 26 patients enrolled, 22 patients were assessable for response and toxicity. When 4 patients entered Level 4, enrollment was closed to avoid severe late toxicities. Dose-limiting toxicities occurred in 3 patients. They were Grade 3 neuropathy at Level 1 and Level 3 and Grade 3 infection at Level 1. However, the maximum tolerated dose was not reached. The median survival time was 28.6 months for all patients. Conclusions: The maximum tolerated dose was not reached, although the dose of radiation was escalated to 72 Gy in 48 fractions. However, a dose of 66 Gy in 44 fractions was adopted for this study because late toxicity data were insufficient.

Original languageEnglish
Pages (from-to)327-331
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume83
Issue number1
DOIs
Publication statusPublished - May 1 2012

Fingerprint

Conformal Radiotherapy
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
lungs
radiation therapy
cancer
toxicity
dosage
grade
Maximum Tolerated Dose
Carboplatin
Paclitaxel
Area Under Curve
Radiotherapy
Thorax
Consolidation Chemotherapy
Esophagitis
fever
consolidation
infectious diseases

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A phase i study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer : WJTOG 3305. / Tada, Takuhito; Chiba, Yasutaka; Tsujino, Kayoko; Fukuda, Haruyuki; Nishimura, Yasumasa; Kokubo, Masaki; Negoro, Shunichi; Kudoh, Shinzoh; Fukuoka, Masahiro; Nakagawa, Kazuhiko; Nakanishi, Yoichi.

In: International Journal of Radiation Oncology Biology Physics, Vol. 83, No. 1, 01.05.2012, p. 327-331.

Research output: Contribution to journalArticle

Tada, Takuhito ; Chiba, Yasutaka ; Tsujino, Kayoko ; Fukuda, Haruyuki ; Nishimura, Yasumasa ; Kokubo, Masaki ; Negoro, Shunichi ; Kudoh, Shinzoh ; Fukuoka, Masahiro ; Nakagawa, Kazuhiko ; Nakanishi, Yoichi. / A phase i study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer : WJTOG 3305. In: International Journal of Radiation Oncology Biology Physics. 2012 ; Vol. 83, No. 1. pp. 327-331.
@article{4512af5d9ff342b69f0bfa644a7b0853,
title = "A phase i study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer: WJTOG 3305",
abstract = "Purpose: A Phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small-cell lung cancer was conducted. Methods and Materials: Patients with unresectable Stage III non-small-cell lung cancer were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m 2) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m 2). Total doses were 54 Gy in 36 fractions, 60 Gy in 40 fractions, 66 Gy in 44 fractions, and 72 Gy in 48 fractions at Levels 1 to 4. The dose-limiting toxicity, defined as Grade ≥4 esophagitis and neutropenic fever and Grade ≥3 other nonhematologic toxicities, was monitored for 90 days. Results: Of 26 patients enrolled, 22 patients were assessable for response and toxicity. When 4 patients entered Level 4, enrollment was closed to avoid severe late toxicities. Dose-limiting toxicities occurred in 3 patients. They were Grade 3 neuropathy at Level 1 and Level 3 and Grade 3 infection at Level 1. However, the maximum tolerated dose was not reached. The median survival time was 28.6 months for all patients. Conclusions: The maximum tolerated dose was not reached, although the dose of radiation was escalated to 72 Gy in 48 fractions. However, a dose of 66 Gy in 44 fractions was adopted for this study because late toxicity data were insufficient.",
author = "Takuhito Tada and Yasutaka Chiba and Kayoko Tsujino and Haruyuki Fukuda and Yasumasa Nishimura and Masaki Kokubo and Shunichi Negoro and Shinzoh Kudoh and Masahiro Fukuoka and Kazuhiko Nakagawa and Yoichi Nakanishi",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2011.06.1991",
language = "English",
volume = "83",
pages = "327--331",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A phase i study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer

T2 - WJTOG 3305

AU - Tada, Takuhito

AU - Chiba, Yasutaka

AU - Tsujino, Kayoko

AU - Fukuda, Haruyuki

AU - Nishimura, Yasumasa

AU - Kokubo, Masaki

AU - Negoro, Shunichi

AU - Kudoh, Shinzoh

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

AU - Nakanishi, Yoichi

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Purpose: A Phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small-cell lung cancer was conducted. Methods and Materials: Patients with unresectable Stage III non-small-cell lung cancer were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m 2) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m 2). Total doses were 54 Gy in 36 fractions, 60 Gy in 40 fractions, 66 Gy in 44 fractions, and 72 Gy in 48 fractions at Levels 1 to 4. The dose-limiting toxicity, defined as Grade ≥4 esophagitis and neutropenic fever and Grade ≥3 other nonhematologic toxicities, was monitored for 90 days. Results: Of 26 patients enrolled, 22 patients were assessable for response and toxicity. When 4 patients entered Level 4, enrollment was closed to avoid severe late toxicities. Dose-limiting toxicities occurred in 3 patients. They were Grade 3 neuropathy at Level 1 and Level 3 and Grade 3 infection at Level 1. However, the maximum tolerated dose was not reached. The median survival time was 28.6 months for all patients. Conclusions: The maximum tolerated dose was not reached, although the dose of radiation was escalated to 72 Gy in 48 fractions. However, a dose of 66 Gy in 44 fractions was adopted for this study because late toxicity data were insufficient.

AB - Purpose: A Phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small-cell lung cancer was conducted. Methods and Materials: Patients with unresectable Stage III non-small-cell lung cancer were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m 2) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m 2). Total doses were 54 Gy in 36 fractions, 60 Gy in 40 fractions, 66 Gy in 44 fractions, and 72 Gy in 48 fractions at Levels 1 to 4. The dose-limiting toxicity, defined as Grade ≥4 esophagitis and neutropenic fever and Grade ≥3 other nonhematologic toxicities, was monitored for 90 days. Results: Of 26 patients enrolled, 22 patients were assessable for response and toxicity. When 4 patients entered Level 4, enrollment was closed to avoid severe late toxicities. Dose-limiting toxicities occurred in 3 patients. They were Grade 3 neuropathy at Level 1 and Level 3 and Grade 3 infection at Level 1. However, the maximum tolerated dose was not reached. The median survival time was 28.6 months for all patients. Conclusions: The maximum tolerated dose was not reached, although the dose of radiation was escalated to 72 Gy in 48 fractions. However, a dose of 66 Gy in 44 fractions was adopted for this study because late toxicity data were insufficient.

UR - http://www.scopus.com/inward/record.url?scp=84859872340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859872340&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2011.06.1991

DO - 10.1016/j.ijrobp.2011.06.1991

M3 - Article

C2 - 22079726

AN - SCOPUS:84859872340

VL - 83

SP - 327

EP - 331

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -